Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: iteostherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/13/2024 | $31.00 | Overweight | Wells Fargo |
| 12/13/2021 | $37.00 → $54.00 | Buy | HC Wainwright & Co. |
| 11/12/2021 | $55.00 → $54.00 | Outperform | SVB Leerink |
| 8/13/2021 | $56.00 → $55.00 | Outperform | SVB Leerink |
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
8-K - iTeos Therapeutics, Inc. (0001808865) (Filer)
10-Q - iTeos Therapeutics, Inc. (0001808865) (Filer)
8-K - iTeos Therapeutics, Inc. (0001808865) (Filer)
8-K - iTeos Therapeutics, Inc. (0001808865) (Filer)
10-Q - iTeos Therapeutics, Inc. (0001808865) (Filer)
8-K - iTeos Therapeutics, Inc. (0001808865) (Filer)
8-K - iTeos Therapeutics, Inc. (0001808865) (Filer)
424B5 - iTeos Therapeutics, Inc. (0001808865) (Filer)
10-Q - iTeos Therapeutics, Inc. (0001808865) (Filer)
ARS - iTeos Therapeutics, Inc. (0001808865) (Filer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
3 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - EOS-984 Phase 1 monotherapy and PD-1 combination data anticipated in 2H25 - EOS-215, a potential best-in-class anti-TREM2 monoclonal antibody, IND submission anticipated in 1Q25 - Cash balance and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 10, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discover
WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 15, 2025 at 7:30 AM PST (10:30 AM EST). A live webcast of the presentation will be available on the Investors section of the Company's website at www.iteostherapeutics.com. An archived replay will be available for approximately 3
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts- Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS- Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no dose-dependent toxicity observed- Inupadenant deprioritized to focus resources on other programs WATERTOWN, Mass. and GOSSELIES, Belgium, Dec. 12, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pione
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December: 7Th Annual Evercore HealthCONx ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: Tuesday, December 3, 2024Time: 9:35 AM ETLocation: Coral Gables, FL Piper Sandler 36th Annual Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: Wednesday, December 4, 2024Time: 11:30 AM ETLocation: New
- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO- Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination- Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the
WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that preclinical, translational, and clinical data from inupadenant will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2024, being held December 11-13, 2024 in Geneva, Switzerland. The clinical and translational data from the dose escalation portion of A2A-005, the Phase 2 trial assessing inupadenant and platinum-doublet chemotherapy in post-immunotherapy me
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy- Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations- GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting- iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET WATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 14, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stag
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in September: 2024 Wells Fargo Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: Wednesday, September 4, 2024Time: 4:30 PM ETLocation: Boston, M.A. Cantor Fitzgerald Global Healthcare ConferenceFormat: Fireside chat and one-on-one meetingsDate: Wednesday, September 18, 2024Time: 10:20 AM ETLocat
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that interim data from GALAXIES Lung-201, the Phase 2 platform study sponsored by iTeos' development partner GSK, assessing the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer, will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024, being held Sep
- Multiple clinical milestones across portfolio anticipated in second half of 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Pro forma cash and investment balance of $714.4 million as of June 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the second quarter ended June 30, 2024 and provided a
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate will be responsible for overseeing the Company's clinical development and regulatory strategies. "As iTeos reaches a pivotal moment towards recognizing our ambition to become a leading oncology company, we're excited to welcome Dr. Feltquate as Chief Medical Officer," said Michel Detheux, Ph.D., presi
WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of Jill DeSimone to its Board of Directors, effective March 7, 2024, where she will serve on the Company's audit committee. "Expanding our board with industry leaders and oncology veterans with commercial, scientific, and corporate portfolio strategy experience is of the utmost importance for iTeos. After the recent appointment of Servier's David Lee, we are thrilled to welcome Jill DeSimone to o
- Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Completed enrollment of third dose cohort in Phase 1 trial of EOS-984- Preclinical presentations on role of ENT1 at SITC Spring Scientific and profile of EOS-984 at AACR annual meeting- Cash and investment balance of $632.7 million as of December 31, 2023 expected to provide runway through 2026 across a number of impactful portfolio milestones- Oncology veterans Jill DeSimone and David K. Lee to join Board of Directors WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NA
NEW YORK, Oct. 11, 2023 /PRNewswire/ -- NCR Atleos Corp. (NYSE:NATL) will replace iTeos Therapeutics Inc. (NASD: ITOS) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 18. S&P MidCap 400 constituent NCR Corp. (NYSE:NCR) is spinning off NCR Atleos in a transaction expected to be completed on October 17. Following the spin-off, the NCR parent will have a name and symbol change to NCR Voyix Corp. (NYSE:VYX) and will remain in the S&P MidCap 400. iTeos Therapeutics is no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Nam
Dr Leroy will oversee the pipeline of the company in immuno-oncology and will be responsible for advancing the GPCR programs to the clinic Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announced that it is strengthening its scientific team with the appointement of Dr Xavier Leroy as CSO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005393/en/Dr Xavier Leroy (Photo: Domain Therapeutics) Based on his widely recognized expertise in GPCRs and immunology, Dr Leroy joined Domain Thera
CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced the appointment of Tony Ho, M.D., and Robert Iannone, M.D., M.S.C.E., to its Board of Directors. They will expand the clinical drug development and strategy expertise of iTeos Board with their track record in leading pharma and biotech companies. "We are thrilled to welcome Tony and Robert to our board as we advance our highly innovative immuno-oncology pipeline programs through clinical deve
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy- Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations- GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting- iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET WATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 14, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stag
- First patients dosed in clinical trial of anti-TIGIT monoclonal antibody, EOS-448, in combination with pembrolizumab and with inupadenant in patients with solid tumors - Advanced clinical development of inupadenant, EOS-850, an A2A receptor antagonist, with initiation of an expansion in PD-1 resistant melanoma in combination with pembrolizumab as well as a planned study further exploring novel predictive biomarkers - Received full upfront payment of $625MM at closing of development and commercialization collaboration agreement with GSK for EOS-448 - Cash balance of $899.8MM as of September 30, 2021, providing runway into 2026 to support clinical development plans for EOS-448 and inupad
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, November 10, 2021 to report its third quarter 2021 financial results and provide a corporate update. To access the live conference call, please dial 833-927-1758 (domestic) or 929-526-1599 (international) and refer to conference access code 861337. A live audio webcast of the event will also be accessible from
Announced co-development and co-commercialization collaboration with GSK for anti-TIGIT monoclonal antibody EOS-448 (GSK'859); $625MM upfront payment in addition to $1.45B in potential milestones, 40/60 cost-sharing of global development, 50/50 profit share in the US, and royalty payments on ex-US sales Presented initial clinical data for EOS-448 at AACR 2021 demonstrating target engagement, promising early monotherapy anti-cancer activity and tolerability at all dose levels Updated data from Phase 1/2a trial of inupadenant (EOS-850) presented at ASCO 2021 show evidence of durable monotherapy anti-cancer activity, and a correlation between the expression of A2AR and clinical outcomes Cash
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 05, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Thursday, August 12, 2021 to report its second quarter 2021 financial results and provide a corporate update. To pre-register for the call, please use the following link, and you will receive access details via email. Webcast This registration link, along with a live audio webcast, will be accessible from the Events pa
Wells Fargo initiated coverage of iTeos Therapeutics with a rating of Overweight and set a new price target of $31.00
HC Wainwright & Co. reiterated coverage of ITeos Therapeutics with a rating of Buy and set a new price target of $54.00 from $37.00 previously
SVB Leerink reiterated coverage of ITeos Therapeutics with a rating of Outperform and set a new price target of $54.00 from $55.00 previously
SVB Leerink reiterated coverage of ITeos Therapeutics with a rating of Outperform and set a new price target of $55.00 from $56.00 previously
SVB Leerink reiterated coverage of ITeos Therapeutics with a rating of Outperform and set a new price target of $45.00 from $60.00 previously
HC Wainwright & Co. initiated coverage of ITeos Therapeutics with a rating of Buy and set a new price target of $37.00
SVB Leerink reiterated coverage of ITeos Therapeutics with a rating of Outperform and set a new price target of $60.00 from $37.00 previously
SC 13G - iTeos Therapeutics, Inc. (0001808865) (Subject)
SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)
SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)
SC 13G/A - iTeos Therapeutics, Inc. (0001808865) (Subject)
SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)
SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)
SC 13G - iTeos Therapeutics, Inc. (0001808865) (Subject)
SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)
SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)
SC 13G - iTeos Therapeutics, Inc. (0001808865) (Subject)